目的 探讨达格列净片联合普伐他汀钠片治疗慢性心力衰竭的临床疗效。方法 选取邢台市中心医院在2022年2月—2023年12月收治的144例慢性心力衰竭患者，根据随机数字表法将所有患者分为对照组和治疗组，每组各72例。对照组口服普伐他汀钠片，2片/次，1次/d。治疗组在对照组基础上口服达格列净片，1片/次，1次/d。两组患者连续治疗2个月。比较两组的临床疗效、病情程度、生活质量、心功能和血清指标。结果 治疗后，与对照组总有效率83.33%比较，治疗组的总有效率94.44%更高，组间差异显著（P＜0.05）。治疗后，两组的心衰评分、明尼苏达心力衰竭生活质量量表（MLHFQ）评分均明显降低（P＜0.05）；治疗组的心衰评分、MLHFQ评分低于对照组（P＜0.05）。治疗后，两组的左室射血分数（EF）显著升高，左心室重塑指数（LVRI）、左心室质量指数（LVMI）显著降低（P＜0.05）；治疗组的EF高于对照组，LVRI、LVMI低于对照组（P＜0.05）。治疗后，两组的血清N端脑钠肽前体（NT-proBNP）、视黄醇结合蛋白4（RBP4）、脂联素（ADP）水平显著降低（P＜0.05）；与对照组比较，治疗组的血清NT-proBNP、RBP4、ADP更低（P＜0.05）。结论 达格列净片联合普伐他汀钠片可提高慢性心力衰竭的治疗效果，显著减轻病情严重程度，改善患者生活质量和心功能，降低心肌损伤。

Objective To investigate the clinical efficacy of Dapagliflozin Tablets combined with Pravastatin Sodium Tablets in treatment of chronic heart failure. Methods Patients (114 cases) with chronic heart failure in Xingtai Central Hospital from February 2022 to December 2023 were divided into control and treatment groups according to the random number method, and each group had 72 cases. Patients in the control group were po administered with Pravastatin Sodium Tablets, 2 tablets/time, once daily. Patients in the treatment group were po administered with Dapagliflozin Tablets on the basis of the control group, 1 tablets/time, once daily. Patients in two groups were treated for 2 months. The clinical efficacies, the degree of illness, the quality of life, the heart function, and the serum indicators in two groups were compared. Results After treatment, the total effective rate of the treatment group was 94.44%, which was higher than 83.33% of the control group, and the difference between groups was significant (P < 0.05). After treatment, the heart failure score and MLHFQ score of two groups were significantly decreased (P < 0.05), and the scores of heart failure and MLHFQ in the treatment group were lower than those in the control group (P< 0.05). After treatment, EF in two groups was significantly increased, but LVRI and LVMI in two groups were significantly decreased (P < 0.05). After treatment, EF in treatment group was higher than that in control group, but LVRI and LVMI in treatment group were lower than that in control group (P< 0.05). After treatment, the serum levels of NT-proBNP, RBP4, and ADP in two groups were significantly decreased (P < 0.05). Compared with the control group, the serum levels of NT-proBNP, RBP4, and ADP in the treatment group were lower (P < 0.05). Conclusion Dapagliflozin Tablets combined with Pravastatin Sodium Tablets can significantly reduce the severity of chronic heart failure, improve the quality of life and cardiac function of patients, and reduce myocardial damage.

R972